Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBITDA (2016 - 2025)

Tandem Diabetes Care's EBITDA history spans 13 years, with the latest figure at -$164000.0 for Q4 2025.

  • For Q4 2025, EBITDA rose 96.76% year-over-year to -$164000.0; the TTM value through Dec 2025 reached -$197.2 million, down 98.48%, while the annual FY2025 figure was -$197.2 million, 98.48% down from the prior year.
  • EBITDA reached -$164000.0 in Q4 2025 per TNDM's latest filing, up from -$19.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $10.2 million in Q4 2021 to a low of -$128.5 million in Q1 2025.
  • Average EBITDA over 5 years is -$29.9 million, with a median of -$18.9 million recorded in 2024.
  • Peak YoY movement for EBITDA: soared 162.4% in 2021, then tumbled 960.91% in 2022.
  • A 5-year view of EBITDA shows it stood at $10.2 million in 2021, then crashed by 223.86% to -$12.6 million in 2022, then tumbled by 109.64% to -$26.4 million in 2023, then surged by 80.85% to -$5.1 million in 2024, then surged by 96.76% to -$164000.0 in 2025.
  • Per Business Quant, the three most recent readings for TNDM's EBITDA are -$164000.0 (Q4 2025), -$19.7 million (Q3 2025), and -$48.7 million (Q2 2025).